



Published on *SWOT Analysis* (<https://www.swotanalysis.info>)

Home > Global ADHD Medication Market Growth (Status and Outlook) 2022-2028

Global ADHD Medication Market Growth (Status and Outlook) 2022-2028

Publication ID:

ARS0122057

Publication Date:

January 08, 2022

Pages:

98

Publisher:

Arsta

Region:

Global [1]

\$3,660.00

Publication License Type *

Single User License (PDF), \$3,660.00

Global License (PDF), \$5,860.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



Description:

As the global economy recovers in 2021 and the supply of the industrial chain improves, the ADHD Medication market will undergo major changes. According to the latest research, the market size of

the ADHD Medication industry in 2021 will increase by USD million compared to 2020, with a growth rate of %.

The global ADHD Medication industry report provides top-notch qualitative and quantitative information including: Market size (2017-2021 value and 2022 forecast). The report also contains descriptions of key players, including key financial indicators and market competitive pressure analysis.

The report also assesses key opportunities in the market and outlines the factors that are and will drive the growth of the industry. Taking into account previous growth patterns, growth drivers, and current and future trends, we also forecast the overall growth of the global ADHD Medication market during the next few years. The global ADHD Medication market size will reach USD million in 2028, growing at a CAGR of % during the analysis period.

This report presents a comprehensive overview, market shares, and growth opportunities of ADHD Medication market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.

Stimulant

Non-stimulant

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.

Attention Deficit

Hyperactivity/impulse Control Disorder

Hybrid

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.

Takeda
Johnson & Johnson
Novartis
Eli Lilly
Tris Pharma, Inc
Neos Therapeutics
Mallinckrodt
Amneal Pharmaceuticals
Noven Pharmaceuticals
Purdue Parma
Zhengda Fenghai

Table Of Contents:

Table of Content

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global ADHD Medication Market Size 2017-2028

- 2.1.2 ADHD Medication Market Size CAGR by Region 2017 VS 2022 VS 2028
- 2.2 ADHD Medication Segment by Type
 - 2.2.1 Stimulant
 - 2.2.2 Non-stimulant
- 2.3 ADHD Medication Market Size by Type
 - 2.3.1 ADHD Medication Market Size CAGR by Type (2017 VS 2022 VS 2028)
 - 2.3.2 Global ADHD Medication Market Size Market Share by Type (2017-2022)
- 2.4 ADHD Medication Segment by Application
 - 2.4.1 Attention Deficit
 - 2.4.2 Hyperactivity/impulse Control Disorder
 - 2.4.3 Hybrid
- 2.5 ADHD Medication Market Size by Application
 - 2.5.1 ADHD Medication Market Size CAGR by Application (2017 VS 2022 VS 2028)
 - 2.5.2 Global ADHD Medication Market Size Market Share by Application (2017-2022)
- 3 ADHD Medication Market Size by Player
 - 3.1 ADHD Medication Market Size Market Share by Players
 - 3.1.1 Global ADHD Medication Revenue by Players (2020-2022)
 - 3.1.2 Global ADHD Medication Revenue Market Share by Players (2020-2022)
 - 3.2 Global ADHD Medication Key Players Head office and Products Offered
 - 3.3 Market Concentration Rate Analysis
 - 3.3.1 Competition Landscape Analysis
 - 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
 - 3.4 New Products and Potential Entrants
 - 3.5 Mergers & Acquisitions, Expansion
- 4 ADHD Medication by Regions
 - 4.1 ADHD Medication Market Size by Regions (2017-2022)
 - 4.2 Americas ADHD Medication Market Size Growth (2017-2022)
 - 4.3 APAC ADHD Medication Market Size Growth (2017-2022)
 - 4.4 Europe ADHD Medication Market Size Growth (2017-2022)
 - 4.5 Middle East & Africa ADHD Medication Market Size Growth (2017-2022)
- 5 Americas
 - 5.1 Americas ADHD Medication Market Size by Country (2017-2022)
 - 5.2 Americas ADHD Medication Market Size by Type (2017-2022)
 - 5.3 Americas ADHD Medication Market Size by Application (2017-2022)
 - 5.4 United States
 - 5.5 Canada
 - 5.6 Mexico
 - 5.7 Brazil

6 APAC

6.1 APAC ADHD Medication Market Size by Region (2017-2022)

6.2 APAC ADHD Medication Market Size by Type (2017-2022)

6.3 APAC ADHD Medication Market Size by Application (2017-2022)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 Europe

7.1 Europe ADHD Medication by Country (2017-2022)

7.2 Europe ADHD Medication Market Size by Type (2017-2022)

7.3 Europe ADHD Medication Market Size by Application (2017-2022)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa ADHD Medication by Region (2017-2022)

8.2 Middle East & Africa ADHD Medication Market Size by Type (2017-2022)

8.3 Middle East & Africa ADHD Medication Market Size by Application (2017-2022)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Global ADHD Medication Market Forecast

10.1 Global ADHD Medication Forecast by Regions (2023-2028)

10.1.1 Global ADHD Medication Forecast by Regions (2023-2028)

10.1.2 Americas ADHD Medication Forecast

10.1.3 APAC ADHD Medication Forecast

10.1.4 Europe ADHD Medication Forecast

- 10.1.5 Middle East & Africa ADHD Medication Forecast
- 10.2 Americas ADHD Medication Forecast by Country (2023-2028)
 - 10.2.1 United States ADHD Medication Market Forecast
 - 10.2.2 Canada ADHD Medication Market Forecast
 - 10.2.3 Mexico ADHD Medication Market Forecast
 - 10.2.4 Brazil ADHD Medication Market Forecast
- 10.3 APAC ADHD Medication Forecast by Region (2023-2028)
 - 10.3.1 China ADHD Medication Market Forecast
 - 10.3.2 Japan ADHD Medication Market Forecast
 - 10.3.3 Korea ADHD Medication Market Forecast
 - 10.3.4 Southeast Asia ADHD Medication Market Forecast
 - 10.3.5 India ADHD Medication Market Forecast
 - 10.3.6 Australia ADHD Medication Market Forecast
- 10.4 Europe ADHD Medication Forecast by Country (2023-2028)
 - 10.4.1 Germany ADHD Medication Market Forecast
 - 10.4.2 France ADHD Medication Market Forecast
 - 10.4.3 UK ADHD Medication Market Forecast
 - 10.4.4 Italy ADHD Medication Market Forecast
 - 10.4.5 Russia ADHD Medication Market Forecast
- 10.5 Middle East & Africa ADHD Medication Forecast by Region (2023-2028)
 - 10.5.1 Egypt ADHD Medication Market Forecast
 - 10.5.2 South Africa ADHD Medication Market Forecast
 - 10.5.3 Israel ADHD Medication Market Forecast
 - 10.5.4 Turkey ADHD Medication Market Forecast
 - 10.5.5 GCC Countries ADHD Medication Market Forecast
- 10.6 Global ADHD Medication Forecast by Type (2023-2028)
- 10.7 Global ADHD Medication Forecast by Application (2023-2028)
- 11 Key Players Analysis
 - 11.1 Takeda
 - 11.1.1 Takeda Company Information
 - 11.1.2 Takeda ADHD Medication Product Offered
 - 11.1.3 Takeda ADHD Medication Revenue, Gross Margin and Market Share (2020-2022)
 - 11.1.4 Takeda Main Business Overview
 - 11.1.5 Takeda Latest Developments
 - 11.2 Johnson & Johnson
 - 11.2.1 Johnson & Johnson Company Information
 - 11.2.2 Johnson & Johnson ADHD Medication Product Offered
 - 11.2.3 Johnson & Johnson ADHD Medication Revenue, Gross Margin and Market Share (2020-2022)
 - 11.2.4 Johnson & Johnson Main Business Overview

- 11.2.5 Johnson & Johnson Latest Developments
- 11.3 Novartis
 - 11.3.1 Novartis Company Information
 - 11.3.2 Novartis ADHD Medication Product Offered
 - 11.3.3 Novartis ADHD Medication Revenue, Gross Margin and Market Share (2020-2022)
 - 11.3.4 Novartis Main Business Overview
 - 11.3.5 Novartis Latest Developments
- 11.4 Eli Lilly
 - 11.4.1 Eli Lilly Company Information
 - 11.4.2 Eli Lilly ADHD Medication Product Offered
 - 11.4.3 Eli Lilly ADHD Medication Revenue, Gross Margin and Market Share (2020-2022)
 - 11.4.4 Eli Lilly Main Business Overview
 - 11.4.5 Eli Lilly Latest Developments
- 11.5 Tris Pharma, Inc
 - 11.5.1 Tris Pharma, Inc Company Information
 - 11.5.2 Tris Pharma, Inc ADHD Medication Product Offered
 - 11.5.3 Tris Pharma, Inc ADHD Medication Revenue, Gross Margin and Market Share (2020-2022)
 - 11.5.4 Tris Pharma, Inc Main Business Overview
 - 11.5.5 Tris Pharma, Inc Latest Developments
- 11.6 Neos Therapeutics
 - 11.6.1 Neos Therapeutics Company Information
 - 11.6.2 Neos Therapeutics ADHD Medication Product Offered
 - 11.6.3 Neos Therapeutics ADHD Medication Revenue, Gross Margin and Market Share (2020-2022)
 - 11.6.4 Neos Therapeutics Main Business Overview
 - 11.6.5 Neos Therapeutics Latest Developments
- 11.7 Mallinckrodt
 - 11.7.1 Mallinckrodt Company Information
 - 11.7.2 Mallinckrodt ADHD Medication Product Offered
 - 11.7.3 Mallinckrodt ADHD Medication Revenue, Gross Margin and Market Share (2020-2022)
 - 11.7.4 Mallinckrodt Main Business Overview
 - 11.7.5 Mallinckrodt Latest Developments
- 11.8 Amneal Pharmaceuticals
 - 11.8.1 Amneal Pharmaceuticals Company Information
 - 11.8.2 Amneal Pharmaceuticals ADHD Medication Product Offered
 - 11.8.3 Amneal Pharmaceuticals ADHD Medication Revenue, Gross Margin and Market Share (2020-2022)
 - 11.8.4 Amneal Pharmaceuticals Main Business Overview
 - 11.8.5 Amneal Pharmaceuticals Latest Developments
- 11.9 Noven Pharmaceuticals
 - 11.9.1 Noven Pharmaceuticals Company Information

- 11.9.2 Noven Pharmaceuticals ADHD Medication Product Offered
- 11.9.3 Noven Pharmaceuticals ADHD Medication Revenue, Gross Margin and Market Share (2020-2022)
- 11.9.4 Noven Pharmaceuticals Main Business Overview
- 11.9.5 Noven Pharmaceuticals Latest Developments
- 11.10 Purdue Parma
 - 11.10.1 Purdue Parma Company Information
 - 11.10.2 Purdue Parma ADHD Medication Product Offered
 - 11.10.3 Purdue Parma ADHD Medication Revenue, Gross Margin and Market Share (2020-2022)
 - 11.10.4 Purdue Parma Main Business Overview
 - 11.10.5 Purdue Parma Latest Developments
- 11.11 Zhengda Fenghai
 - 11.11.1 Zhengda Fenghai Company Information
 - 11.11.2 Zhengda Fenghai ADHD Medication Product Offered
 - 11.11.3 Zhengda Fenghai ADHD Medication Revenue, Gross Margin and Market Share (2020-2022)
 - 11.11.4 Zhengda Fenghai Main Business Overview
 - 11.11.5 Zhengda Fenghai Latest Developments

12 Research Findings and Conclusion

Companies Mentioned:

Takeda
Johnson & Johnson
Novartis
Eli Lilly
Tris Pharma, Inc
Neos Therapeutics
Mallinckrodt
Amneal Pharmaceuticals
Noven Pharmaceuticals
Purdue Parma
Zhengda Fenghai

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other

person or persons.

- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

No. 1101, Golden Square, 3rd Floor,
24th Main, J P Nagar, 1st Phase,
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

NAVIGATE

[About Us](#)

[Reports by Region](#)

[FAQ](#)

[Privacy Policy](#)

[TERMS & CONDITIONS](#)

[CONTACT](#)

RECENT POSTS

[What is SWOT Analysis?](#)

March 12

[How to use market research to bring your idea to life?](#)

March 11

[How to gain business insights using syndicated market research?](#)

March 10

Source URL:<https://www.swotanalysis.info/arsta/global-adhd-medication-market-growth-status-and-outlook-2022-2028>

Links

[1] <https://www.swotanalysis.info/region/global>